(click on the image above to view the video)

Recorded at the IMF Satellite Symposium that was held at the May 2018 Oncology Nursing Society’s annual meeting, this video is the second in a three-part series on myeloma nursing. In this segment, Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN (Taussig Cancer Insitute, Cleveland Clinic, Cleveland, OH) and Kevin Brigle, PhD, NP discuss newly diagnosed multiple myeloma, response, bone health, renal health, minimal residual disease, survivorship care, relapsed myeloma, multiple therapeutic options, and inmmunotherapy considerations. 



Other Topics:


This activity is supported by educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Oncology, and educational funding donation provided by Amgen Oncology

Previous Post
Multiple Myeloma Background, Shared Decision Making, and Smoldering Update
Next Post
Myeloma Updates 2018: Best of ASCO/EHA/IMWG

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.